Glucagon-like peptide 1 7-36 amide intranasal - Asubio Pharma

Drug Profile

Glucagon-like peptide 1 7-36 amide intranasal - Asubio Pharma

Alternative Names: CS 872; SUN E7001

Latest Information Update: 09 Feb 2010

Price : $50

At a glance

  • Originator Asubio Pharma; Daiichi Sankyo Company
  • Developer Asubio Pharma
  • Class Glucagon-like peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 01 Apr 2007 Daiichi Asubio Pharma is now called Asubio Pharma
  • 11 Aug 2006 Preclinical trials in Type-2 diabetes mellitus in World (Intranasal)
  • 11 Aug 2006 Phase-I clinical trials in Type-2 diabetes mellitus in Japan (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top